Effect of a Hypocretin/Orexin Antagonist on Neurocogniive Performance
Annual rept. 1 Sep 2013-31 Aug 2014
SRI INTERNATIONAL MENLO PARK CA
Pagination or Media Count:
During Year 5, we continued tests of the hypothesis that disfacilitation of wake-promoting systems by the hypocretin Hcrt receptor antagonist almorexant ALM results in less functional impairment than the inhibition of neural activity produced by the benzodiazepine receptor agonist zolpidem ZOL. One paper was published Morairty et al. 2014, another has been accepted for publication Dittrich et al., in press and a third is in resubmission Vazquez-DeRose et al., submitted. Data collection for Aims 2c and 3b.2 have been completed and data analysis ongoing manuscripts will be written and submitted during Year 6. Data collection and analysis of Aim 3a is nearing completion an abstract summarizing this work has been submitted for presentation at the 2014 Society for Neuroscience meeting. Data collection for Aims 3b.3, 4c and 6a have been initiated. The overall results obtained to date are consistent with the hypothesis that the hypocretinorexin antagonist ALM produces less functional impairment than the benzodiazepine receptor agonist zolpidem ZOL because ZOL causes a general inhibition of neural activity whereas ALM specifically disfacilitates wake-promoting systems.
- Medicine and Medical Research
- Stress Physiology